Inactive Instrument
Claritas Pharmaceuticals Stock Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.86M 3.34M 3.13M 2.86M 368M 5.45M 36.82M 14.39M 184M 14.48M 14.17M 614M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.52M 3.91M 3.67M 3.34M 431M 6.39M 43.13M 16.86M 216M 16.96M 16.59M 719M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| -1.60% | +0.86% | +3.70% | +14.57% | 49.54B | |
| +0.47% | +4.79% | +486.36% | +589.17% | 44.06B | |
| -0.04% | +9.64% | +24.65% | +75.93% | 40.85B | |
| -0.20% | +2.99% | +30.77% | +10.45% | 40.14B | |
| -4.04% | +8.72% | +22.60% | +48.00% | 34.17B | |
| -0.60% | +2.31% | +30.93% | +126.39% | 16.9B | |
| +1.20% | +5.83% | - | - | 16.78B | |
| -0.43% | -0.11% | +4.22% | +20.71% | 14B | |
| +1.49% | +9.71% | +87.25% | +31.87% | 13.46B | |
| Average | +0.73% | +6.97% | +86.31% | +114.63% | 29.99B | |
| Weighted average by Cap. | -0.69% | +6.51% | +104.23% | +137.07% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.24M -13.2M -12.37M -11.28M -1.45B -21.54M -145M -56.87M -728M -57.21M -55.97M -2.43B | 4.21M 3.02M 2.62M 2.46M 2.24M 288M 4.27M 28.88M 11.29M 144M 11.36M 11.11M 482M |
| Net Debt | 704K 506K 438K 411K 374K 48.24M 715K 4.83M 1.89M 24.15M 1.9M 1.86M 80.54M | 920K 661K 573K 537K 489K 63.04M 934K 6.31M 2.47M 31.56M 2.48M 2.43M 105M |
Employees
-
